SCHEMBL19277995

SCHEMBL19277995

CC(C)(O)CC(=O)Nc1nc2ccc(C(F)(F)F)nc2n1-c1ccc(F)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.36
PDE4B Q07343 1/20 0.36
CNR1 P21554 4/20 0.35
CNR2 P34972 2/20 0.35
TRPV1 Q8NER1 2/20 0.35
NR1I2 O75469 1/20 0.35
RORC P51449 1/20 0.35
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
GLA P06280 1/20 0.33
CSNK1D P48730 1/20 0.33
P2RX3 P56373 2/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
CDK8 P49336 1/20 0.33
CLK2 P49760 1/20 0.33
ACVR1 Q04771 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
DYRK1B Q9Y463 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19277997 0.94 PDE2A (0.38) PDE2ACNR1TRPV1NR1I2RORC
SCHEMBL19278014 0.88 BRD4 (0.37) PDE2ACSNK1D
SCHEMBL19277990 0.86 GRM5 (0.41) PDE2ACNR1NR1I2RORCNR1H2
SCHEMBL19277983 0.85 PDE2A (0.35) PDE2APDE4BCNR1TRPV1CSNK1D
SCHEMBL16084438 0.83 P2RX3 (0.39) PDE2ACNR1CNR2MAPTCSNK1D
SCHEMBL19278417 0.83 PDE2A (0.38) PDE2APDE4BTRPV1CSNK1DIRAK4
SCHEMBL19276147 0.82 KCNQ2 (0.41) PDE4BCNR1CNR2MAPTTHRB
SCHEMBL19277821 0.82 PDE4B (0.38) PDE2APDE4BMAPTCSNK1DIRAK4
SCHEMBL19278278 0.81 PDE2A (0.37) PDE2ACSNK1DP2RX3IRAK4LMNA
SCHEMBL19278016 0.80 CSNK1D (0.40) PDE2APDE4BCNR1CNR2CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11724990-B2 Kv7 channel activators compositions and methods of use BIOHAVEN THERAPEUTICS LTD. (VG) 2023-08-15 US disclosed
US-20230000831-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE CHANNEL BIOSCIENCES, LLC 2023-01-05 US disclosed
US-10851067-B2 Kv7 channel activators compositions and methods of use KNOPP BIOSCIENCES LLC (US) 2020-12-01 US disclosed
US-20190284142-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE CHANNEL BIOSCIENCES, LLC 2019-09-19 US disclosed
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2019-01-03 US disclosed
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284142-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE KCNA7, KCNK17, KCNAB1 PDE2A 1992/4885PDE4B 1591/4885CNR1 1114/4885
US-11724990-B2 Kv7 channel activators compositions and methods of use KCNA7, KCNK17, KCNAB1 PDE2A 1992/4885PDE4B 1591/4885CNR1 1114/4885
US-20230000831-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE KCNA7, KCNK17, KCNAB1 PDE2A 1992/4885PDE4B 1591/4885CNR1 1114/4885
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 PDE2A 917/4885PDE4B 802/4885CNR1 353/4885
US-20170240547-A1 IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 PDE2A 859/4885PDE4B 717/4885CNR1 355/4885
US-10851067-B2 Kv7 channel activators compositions and methods of use KCNA7, KCNK17, KCNAB1 PDE2A 1992/4885PDE4B 1591/4885CNR1 1114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.